Intervacc AB (publ) is a Swedish biotechnology company developing breakthrough vaccines based on recombinant protein fusions. In March, the company will present at the DNB/Carnegie Healthcare Seminar, Stora Aktiedagarna ... Read more
The scientific journal Vaccine has published an article entitled "Sow vaccination with a novel recombinant protein vaccine protects piglets against Streptococcus suis infection" (Read more
Stockholm, June 13th, 2024 – Intervacc AB (publ) has presented new reports highlighting the importance of vaccination to disease control strategies and the safety and efficacy of Strangvac® in the field at ... Read more
Stockholm, November 15, 2023 – On Thursday, November 16, 2023 at 08.30 a.m. (CET) Intervacc AB (publ) will publish the Interim report Q3 (July-September), 2023. Following the report’s publication, Intervacc will arrange ... Read more